A quiet six months for device approvals
The second half of 2019 saw half as many innovative medical devices approved as the first.
Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Last-ditch rally saves 2019 float tally
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
